Millennium Pharmaceuticals, Inc. has made two significant advancements in its Aurora A kinase program. The company achieved positive preliminary results from a Phase I study of MLN8054, a first-in-class small molecule to the Aurora A kinase. Also, the company has initiated a new Phase I program for MLN8237, a second-generation Aurora A kinase inhibitor. Aurora A kinases are required for cancer cells to divide and create tumors. In preclinical models, the inhibition of Aurora A kinases has b...